drugset / Trial / NCT00298324
Myfortic - Treatment for Extensive cGvHD
Phase 3
Terminated
34 enrolled
European Society for Blood and Marrow Transplantation
Novartis · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether the response to treatment for extensive chronic Graft versus Host Disease (cGvHD)is improved with the addition of myfortic alongside cyclosporine A and prednisone, compared to the reference treatment of cyclosporine A and prednisone alone.
Timeline
- Start
- 2006-09
- Primary completion
- 2009-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | mycophenolic acid | Small molecule | 1440 mg | — |
| Background | Cyclosporine | Peptide | — | — |
| Background | Prednisone | Other / unclassified | — | — |